Sera Prognostics, Inc. Q4 2025 Earnings Call Summary

Sera Prognostics, Inc. Q4 2025 Earnings Call Summary - Moby

Strategic Transition from Clinical Validation to Market Adoption

The company successfully transitioned from a research-heavy phase to commercialization following the January 2026 publication of the PRIME study in the Pregnancy Journal. PRIME data demonstrated a 56% reduction in births before 32 weeks and a 32% reduction before 35 weeks when using biomarker-based risk identification paired with preventive protocols. Management rebranded 'Medicaid pilot programs' as 'Partner Programs' to reflect a broader scope that includes commercial payers, health systems, and employer collaboratives. Strategic focus has shifted toward high preterm birth burden states, with engagement expanding from 6 to 13 states during 2025 to build local market density. Operational improvements focused on clinical workflow integration, including peer-to-peer education and digital platforms to drive repeat ordering among early adopters. International expansion is progressing with European dossiers for the PreTRM Global test expected for submission in the coming months to secure CE marking.

2026 Commercial Milestones and Growth Strategy

Management expects to expand active state discussions to 15-17 states by the end of 2026, representing approximately 58% to 60% of U.S. births. The company aims to scale from two live partner programs to between five and seven active programs by year-end 2026. Revenue growth is projected to build gradually as partner programs mature and real-world evidence results are disseminated to payers. Capital allocation will prioritize market access and commercial scale-up, with R&D expenses expected to decrease as resources shift to sales and awareness building. The current cash position of $95.8 million is projected to fund operations and commercial milestones through 2028.

Structural Changes and Risk Management

The leadership team was bolstered by the 2025 appointments of the Chief Commercial Officer and Chief Medical Officer, along with the addition of a new Head of Sales, to drive the company's commercialization strategy and 2026 expansion. A new 'at-the-market' (ATM) facility was reestablished to provide financial flexibility, though management stated there are no immediate plans to issue shares. State legislatures and Medicaid agencies are increasingly exploring mandates or budget appropriations for PreTRM coverage, driven by health equity and fiscal concerns. Management noted that while interest is high post-publication, adoption is expected to be gradual as clinical habits and reimbursement pathways are established.

Story Continues

Q&A Session Insights

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Economic and clinical data requirements for payer contracting

Payers are specifically focused on the 20% reduction in NICU admissions shown in PRIME sub-analyses as a primary driver for cost savings. Partner programs allow entities to model PreTRM as a standard of care against their specific patient populations to validate health economic outcomes. Management is sharing internal economic models with partners now while awaiting formal publication of deeper health economic research.

Feedback and engagement trends following the SMFM conference

Management reported a 'marked improvement' in engagement across providers, payers, and state legislators in the 10 weeks since the PRIME publication. Discussions with the Society for Maternal-Fetal Medicine (SMFM) are focused on guideline evolution and making the test more accessible to providers. The publication has provided the necessary 'RCT level evidence' to gain credibility with guideline-setting bodies.

Profile and scalability of new partner programs

The second active partner is an employer collaborative that is multistate, providing a clear path for geographic expansion beyond the initial launch state. Partnership models are being customized to include large IDNs, provider-payers, and former PRIME study sites transitioning to standard-of-care usage. The strategy involves capturing diverse adopters ranging from midwife associations to telehealth pregnancy services.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

View Comments